Regadenoson, a selective A2A receptor agonist, is widely used for vasodilator stress myocardial perfusion imaging and has a superior adverse effect profile when compared with other agents. However, with widespread use, there have been several reported cases of Regadenoson induced bradyarrhythmias and even asystole in patients with no known conduction system disease. In this article, we report a case of asystole following Regadenoson administration, evaluate mechanisms and risk factors for Regadenoson induced bradyarrhythmias to better identify patients at risk. We also review the available treatment options and propose recommendations for limiting its risk.

中文翻译：

---

Regadenoson 给药后出现心搏停止：文献回顾、危险因素和管理

Regadenoson 是一种选择性 A2A 受体激动剂，广泛用于血管舒张应激性心肌灌注成像，与其他药物相比，具有优异的不良反应特征。然而，随着广泛使用，已经有几例报告称雷加德诺森引起缓慢性心律失常，甚至在没有已知传导系统疾病的患者中出现心搏停止。在本文中，我们报告了一例 Regadenoson 给药后出现心搏停止的病例，评估了 Regadenoson 引起的缓慢性心律失常的机制和危险因素，以更好地识别有风险的患者。我们还审查了可用的治疗方案并提出了限制其风险的建议。